Last reviewed · How we verify
Decolonization
At a glance
| Generic name | Decolonization |
|---|---|
| Also known as | Mupirocin |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Oral Microbiota on MDRO Decolonization (PHASE1, PHASE2)
- Effectiveness of the Decolonization Circuit of S. Aureus, Reducing Infection in Primary Arthroplasty of the Lower Limb
- FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae (PHASE1, PHASE2)
- Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (PHASE2)
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections (PHASE3)
- Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada (NA)
- Steriwave ICU Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Decolonization CI brief — competitive landscape report
- Decolonization updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Saint Etienne portfolio CI